The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Thank you. Good morning. Eric, welcome aboard. I just wondered just if you could talk a little bit about the medical side since, obviously, most of
the growth to this point and most of the revenues, the vast majority have been dental. And there's been this Medicare Part B coverage which we
hoped would drive adoption, but it's been -- it has been a very slow process on the medical side. Can you talk about how many facilities have
adopted the CompuFlo system on the Medicaid?
And then what specifically you intend to do to try to drive adoption at a much accelerated rate or get that moving in the right direction? I know
you hired a new Head of Sales. So if you could talk about what you're going to do differently than what prior management has done on the medical
side?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. So Jason is hired. And I know you just recently joined, Eric, but have there been other hires either under Jason or other key hires or if Jason
has a team that he's identified. Have those individuals been offered positions yet and approximately how many other key people do you think you
need to hire to implement what you just outlined?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. Any other maybe just high level, Eric, as you've evaluated the company in general, any other obvious changes or direction that you want to
take the company that you've evaluated and noticed that needs to happen as soon as possible?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay. And then last question is about international. Was what percent of revenues this quarter? And what drove the growth in international this
quarter?
Question: Anthony Vendetti - Maxim Group LLC - Analyst
: Okay, very helpful. Thanks so much. Welcome aboard again and good luck. We concur that you have a, we think, a market-changing product on
the medical side and a great opportunity in front of you. So with that, I'll hop back in the queue.
Question: Bruce Jackson - Benchmark Company LLC - Analyst
: Thank you. Good morning, Eric and Jason, welcome aboard. Wanted to look at the international number a little bit more. What was the role of
tariffs in the quarter? And was there any behavior where there were some international stocking to avoid the tariffs? Or are tariffs just really now
a factor in your business? It sounds like you had some new distributors come online, but I'm just trying to kind of gauge the lumpiness in this
business given the market dynamics?
Question: Bruce Jackson - Benchmark Company LLC - Analyst
: Okay. Great. And then turning over to the reimbursement side of it with the JMAC coverage and the private payers. Is there anything in the funnel
right now? And could we -- do you have anything near term in terms of adding either more JMACs or more private payers to the reimbursement?
Or is the idea to just kind of go deeper in the regions that you've currently got reimbursement for?
Question: Bruce Jackson - Benchmark Company LLC - Analyst
: Okay, great. Thank you for taking my questions. That's it from me.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 15, 2025 / 12:00PM, MLSS.A - Q2 2025 Milestone Scientific Inc Earnings Call
| 
